Glow Expands Technology Portfolio and Proprietary Product Format Capabilities; Develops New Water-Soluble Cannabis Powder Technology

TORONTO, July 6, 2023 – Glow LifeTech Corp. (CSE: GLOW) (OTCQB: GLWLF) (FSE: 9DO) (“Glow” or the “Company”), a biotech innovator producing next-generation, science-backed natural ingredients, is pleased to announce that it has developed a proprietary, water-soluble cannabis powder technology (“New Powder Technology”), which expands the Company’s technology portfolio to both liquid and powder cannabinoid ingredients and unlocks a new range of product format capabilities. To protect the New Powder Technology, the Company has submitted provisional patent applications with the United States Patent and Trademark Office. 

The Company’s New Powder Technology creates dry powder cannabinoids that are water-soluble and designed for improved absorption, great taste and a more consistent and predictable cannabis experience. Building on the Company’s existing nature-based liquid MyCell® Technology, the New Powder Technology is uniquely made with only natural, plant-based ingredients, and cannabis extracts including THC, CBD, CBN and CBG distillates and isolates. The new powder ingredients expands Glow’s growing portfolio of high-performance ingredients, and allows the Company to support a variety of new product formats including capsules, drink mixes, gummies, infused-foods, and more.  

This new powder technology, developed fully in-house, demonstrates our continued focus on developing proprietary, science-driven solutions that unlock a step-change in what’s possible in cannabis and natural health,” said Tom Glawdel, Chief Operating Officer, Glow LifeTech. “Expanding our technology portfolio to include an all-natural, fast-acting, and neutral tasting cannabis powder, opens up several new and important product format capabilities for Glow.

We’re thrilled to bring to market another cutting-edge technology as it positions us well to capture several new growth opportunities in proven cannabis product segments like drink mixes, capsules, infused-foods, and beyond,” said Rob Carducci, Chief Commercial Officer, Glow LifeTech. “Having a complete portfolio of proprietary, market-leading technologies, in both liquid and powder format, ultimately gives us incredible flexibility in what products we can formulate and commercialize.”

The Company submitted provisional patent applications to the United States Patent and Trademark Office (USPTO) as part of its ongoing IP strategy for the powder technology. The filings allow Glow to ascribe the phrase “patent pending” to any commercial products, methods, or services contemplated by the subject matter claimed. The patent applications reflect Glow’s strategy of strengthening its IP portfolio relating to cannabis and nutraceutical ingredient technologies.

MyCell® Technology is Glow’s proprietary delivery system that optimizes the absorption, bioavailability and effectiveness of natural active compounds including vitamins, cannabinoids and botanicals, using only 100% natural, food-grade components. It transforms poorly absorbed natural compounds into water-compatible concentrates that have fast-acting onset, high-absorption, precision dosing and a clean taste profile. With its portfolio of industry-leading ingredients, Glow is powering a new era of more efficient, fast-acting, and great tasting functional foods, beverages, supplements, and personal care products.

SUBSCRIBE: For more information on Glow or to subscribe to the Company’s mail list visit:

About Glow LifeTech Corp.
Glow LifeTech is a Canadian-based biotechnology company focused on producing nutraceutical and cannabinoid-based products with dramatically enhanced bioavailability, absorption and effectiveness. Glow has rights to the groundbreaking, plant-based MyCell Technology® delivery system, which transforms poorly absorbed natural compounds into enhanced water-compatible concentrates that unlock the full healing potential of the valuable compounds.


James Van Staveren
Glow LifeTech Corp.
TF. 855-442-GLOW (4569)

Bernhard Langer
EU Investor Relations
+49 (0) 177 774 2314

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law.   Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur.   Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE.  There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control.  There are no assurances that the commercialization plans for the technology described in this news release will come into effect on the terms or time frame described herein.   The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law.   The reader is cautioned not to place undue reliance on forward-looking statements.   Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which filings are available at

Back to all news